Journal of Jishou University(Natural Sciences Edition) ›› 2021, Vol. 42 ›› Issue (6): 54-61.DOI: 10.13438/j.cnki.jdzk.2021.06.009

• Medical Science • Previous Articles     Next Articles

Progress in the Diagnosis and Treatment of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

ZHANG Rujiang, ZHANG Yunzhou, GAO Daiquan   

  1. (1.Ruili People's Hospital, Ruili 678600, Yunnan China; 2. Xuanwu Hospital of Capital Medical University, Beijing 100053, China)
  • Online:2021-11-25 Published:2022-01-21

Abstract: In order to further improve the understanding of primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), PubMed, CNKI and other databases were used to search related literature on the diagnosis and treatment of primary central nervous system lymphoma, and then The pathogenesis, clinical manifestations, diagnostic methods and treatment measures of PCNS-DLBCL are reviewed. PCNS-DLBCL is a subtype of extranodal non-Hodgkin’s lymphoma that can affect any part of the central nervous system. Its pathogenesis includes the presence of Epstein-Barr virus, increased expression of PD-L1 and PD-L2, MYD88 gene mutation and CD79B Gene mutations, etc.; clinical manifestations lack specificity, high degree of malignancy, easy to relapse, and poor prognosis; diagnostic methods include imaging examination, cerebrospinal fluid examination, immunohistochemistry and histopathological examination, pathological examination is the gold standard for diagnosis; PCNS-DLBCL treatment measures include radiotherapy, chemotherapy, autologous stem cell transplantation, and combined radiotherapy and chemotherapy. At present, induction chemotherapy based on high-dose methotrexate is the best treatment plan.

Key words: diffuse large B-cell lymphoma, central nervous system, diagnostic methods, treatment measures, methotrexate

WeChat e-book chaoxing Mobile QQ